Ventana poised to join Roche
This article was originally published in Clinica
Roche has secured 94% of the shares of Ventana Medical Systems, following the expiration of the tender offer period last week for the Tucson, Arizona-based cancer diagnostics company. A Roche spokesperson told Clinica that the Swiss drugs group is currently in the process of acquiring the remaining shares through a short-form merger. This will be carried out without a vote or meeting with Ventana's shareholders, said Roche. On completion of the acquisition, Ventana's shares will cease trading on the Nasdaq. Roche had endured Ventana's repeated rebuffs for seven months before succeeding in winning over the latter with a sweetened $89.50-per-share offer (see Clinica No 1291, p 3).
You may also be interested in...
COVID-19 Vaccines: ACIP’s Allocation Proposal Prioritizes Long-Term Care Residents, Essential Workers
First group to receive vaccine would comprise health care personnel and residents of long-term care facilities; next in line are non-health care essential workers, who would take priority over adults with high-risk medical conditions and those ages 65 years and older, according to the CDC advisory committee’s proposed allocation framework.
Azar says ACIP’s prioritization recommendations should carry weight, but states will be final arbiter of who is vaccinated.
Sanofi R&D head John Reed says the company has kept 95% of patients on its nearly 400 clinical trials, started 59 studies, and benefited from its in-house drug supply management.